Follow-on rifaximin for the prevention of recurrence following standard treatment of infection with Clostridium difficile: a competing risks analysis provides a full picture of possible treatment effects

Gut. 2020 Feb;69(2):398-400. doi: 10.1136/gutjnl-2018-317839. Epub 2018 Dec 28.

Authors

Maja Katharina von Cube¹, Martin Schumacher¹, Martin Wolkewitz¹; COMBACTE-MAGNET Consortium

Affiliation

¹ Faculty of Medicine and Medical Center, Institute for Medical Biometry and Statistics, University of Freiburg, Freiburg, Germany.

PMID: 30593454
DOI: 10.1136/gutjnl-2018-317839

No abstract available

Keywords: infectious diarrhoea.

Publication types

Letter
Research Support, Non-U.S. Gov't
Comment

MeSH terms

Clostridioides difficile*
Enterocolitis, Pseudomembranous*
Humans
Recurrence
Rifamycins*
Rifaximin

Substances

Rifamycins
Rifaximin